ERBB2 and breast carcinoma: As shown in a mouse model of HER2+ (Erb-B2 Receptor Tyrosine Kinase 2) breast cancer, a permissive effect is also attributed to TAMs for the entry into the bloodstream of circulating tumor cells (CTC) [132].